In its announcement of the delay, the company said it is still growing and profitable, with 5.7 million users, and it plans to post 90% growth for its 2026 fiscal year, ending today.
“We aim to deliver an extraordinary IPO for our employees and investors, and we have the luxury of choosing our moment,” said CEO Tom Hale. “In the meantime, we will execute against the opportunities ahead.”
A report from CNBC noted that Oura’s postponement is only the latest to hit Wall Street. It pointed to record-high yields in the bond market as a potential driver, with the wearable maker being the fourth to reschedule this month among a total of seven in the third quarter across multiple sectors.
Following Oura’s Sept. 21 kickoff — with plans to sell a total of 50 million shares between $40 and $44 apiece, starting Sept. 29 under the ticker OURA — Bloomberg reported last week the IPO was about four-times oversubscribed, with banks expected to stop taking orders from investors early.
Related: Resmed, Oura partner on sleep health education, care
Oura has raised more than $1.5 billion in venture capital funding, including more than $900 million through a Series E round in October 2025 led by Fidelity Management.
In its IPO prospectus filed with the Securities and Exchange Commission, the company reported $1.21 billion in revenue for the nine months ending in June, up 74% from the $698 million in the same period the year prior, raising net income to $60.8 million up from $1.6 million.
More on Medical Design & Outsourcing from early this month: Oura discloses pay packages for top executives ahead of IPO
